Dr. Shana Kelley is a Distinguished Professor of Chemistry, Pharmaceutical Sciences, Biochemistry, and Biomedical Engineering at the University of Toronto. Dr. Kelley received her Ph.D. from the California Institute of Technology and was a NIH postdoctoral fellow at the Scripps Research Institute. The Kelley research group works in a variety of areas spanning biophysical/bioanalytical chemistry, chemical biology and nanotechnology, and have pioneered new methods for tracking molecular and cellular analytes with unprecedented sensitivity. Dr. Kelley’s work has been recognized with a variety of distinctions, including being named one of “Canada’s Top 40 under 40”, a NSERC E.W.R. Steacie Fellow, the 2011 Steacie Prize, and the 2016 NSERC Brockhouse Prize. She has also been recognized with the ACS Inorganic Nanoscience Award, Pittsburgh Conference Achievement Award, an Alfred P. Sloan Research Fellowship, a Camille Dreyfus Teacher-Scholar award, a NSF CAREER Award, a Dreyfus New Faculty Award, and was also named a “Top 100 Innovator” by MIT’s Technology Review. Shana is a founder of two molecular diagnostics companies, GeneOhm Sciences (acquired by Becton Dickinson in 2005) and Xagenic Inc. (acquired by General Atomics in 2017), and sits on the Board of Directors of the Ontario Genomics Institute and the Fight Against Cancer Trust. She is an Associate Editor for ACS Sensors, and an Editorial Advisory Board Member for the Journal of the American Chemical Society and ACS Chemical Biology.